ARCA biopharma, Inc. (ABIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABIO Stock Price Chart Interactive Chart >
ABIO Price/Volume Stats
| Current price | $2.22 | 52-week high | $2.70 |
| Prev. close | $2.27 | 52-week low | $1.74 |
| Day low | $2.18 | Volume | 40,078 |
| Day high | $2.31 | Avg. volume | 50,106 |
| 50-day MA | $2.26 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 31.99M |
ARCA biopharma, Inc. (ABIO) Company Bio
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Latest ABIO News From Around the Web
Below are the latest news stories about ARCA BIOPHARMA INC that investors may wish to consider to help them evaluate ABIO as an investment opportunity.
James Flynn Joins ARCA biopharma Board of DirectorsWESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium |
One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous yearViewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were... |
ARCA biopharma Announces Third Quarter 2022 Financial ResultsCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine |
ARCA biopharma Announces Second Quarter 2022 Financial ResultsCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr |
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
ABIO Price Returns
| 1-mo | -5.93% |
| 3-mo | 2.04% |
| 6-mo | -9.39% |
| 1-year | 23.33% |
| 3-year | -60.00% |
| 5-year | -93.42% |
| YTD | -6.33% |
| 2022 | 10.23% |
| 2021 | -46.38% |
| 2020 | -29.78% |
| 2019 | -3.86% |
| 2018 | -75.56% |
Loading social stream, please wait...